Date: 2013-09-13
Type of information: Licensing agreement
Compound: lucitanib
Company: Servier (France) Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
licensing
Action mechanism: Lucitanib is a kinase inhibitor which targets fibroblast growth factor receptor 1-2 (FGFR1-2), and vascular endothelial growth factor receptor-1-3 (VEGFR-1-3). This unique activity profile confers on lucitanib specific antitumor activity in FGFR1-2 dependent tumors and a strong antiangiogenic effect.
Disease:
Details: * On September 13, 2013,Servier has concluded a collaboration and license agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM) for the development in China of lucitanib, a targeted antitumor drug with antiangiogenic effects. Results presented at the European Society for Medical Oncology 2012 Congress on the breast cancer cohort of a Phase-I study put lucitanib firmly on the list of the most promising breakthroughs in oncology. In September of the same year, Servier acquired the worldwide rights for lucitanib except for the People’s Republic of China, Japan and the United States.
Servier extends now its rights to China in sealing a collaboration and license agreement with SIMM and other stake holders in China, notably ADVENCHEN and SFFT. The aim of the present agreement between SIMM and Servier is to provide evidence of the clinical benefits of lucitanib in specific Chinese indications through national clinical studies involving Haihe Pharmaceuticals, a local pharmaceutical company created by SIMM.
In addition, SIMM will conduct specific research in biomarkers and support Servier regarding the participation of China in international clinical studies. Under the terms of this agreement, SIMM and Servier will be co-owners of the marketing authorizations for the People’s Republic of China.
Financial terms:
Latest news:
